ACTa1 ELISA kit
- Known as:
- ACTa1 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-ACTa1-Ra
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- ACTa1 ELISA kit
Related genes to: ACTa1 ELISA kit
- Gene:
- ACTA1 NIH gene
- Name:
- actin alpha 1, skeletal muscle
- Previous symbol:
- ACTA
- Synonyms:
- NEM3
- Chromosome:
- 1q42.13
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: ACTa1 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: ACTa1 ELISA kit
- Cardiac hypertrophy plays an important role in organ damage caused by hypertension and may progress into heart failure. This study investigated the function and underlying mechanisms of phosphofurin acidic cluster sorting protein 2 (PACS2) in relation to cardiac hypertrophy. - Source: PubMed
Publication date: 2026/05/14
Shen ZhijieZhang YinzhuangFang Li - Genetic disorders are major causes of morbidity and mortality in neonatal intensive care units (NICUs), yet traditional tests like karyotyping and chromosomal microarray (CMA) often fail to provide a diagnosis, resulting in a "diagnostic odyssey". Trio whole-genome sequencing (WGS) has emerged as a comprehensive tool capable of detecting a wide range of variants beyond protein-coding regions, potentially offering higher diagnostic yields and rapid, actionable results for critical care management. - Source: PubMed
Publication date: 2026/05/15
Kim Hyun HoChang Yun SilPark Woong-YangPark Joonhong - Kampung Unggul Balitbangtan (KUB) chicken is a superior Indonesian native breed with high adaptability, good growth potential, and desirable meat quality. Nutritional strategies such as multienzyme supplementation are increasingly applied to improve productivity and meat quality without altering basal diet composition. This study investigated the effects of dietary multienzyme supplementation, consisting of phytase and protease, on growth performance, carcass characteristics, organ development, meat quality, and muscle-related gene expression in KUB chickens. Sixteen one-day-old male KUB chicks were randomly allocated to four dietary treatments: a control diet without multienzymes and three diets supplemented with phytase (200 mg/kg) combined with protease at 300, 500, or 700 mg/kg of feed. Growth performance parameters were measured up to 45 days of age, followed by carcass evaluation, organ weight analysis, meat quality assessment, and transcriptomic and quantitative real-time PCR analyses of breast muscle tissue. Multienzyme supplementation significantly improved final body weight and feed conversion ratio, particularly during the finisher phase, while reducing feed intake at higher enzyme inclusion levels. Carcass percentage and breast weight were enhanced in multienzyme-treated groups, accompanied by favorable changes in digestive and immune organ development. Meat quality analysis showed increased water-holding capacity, reduced cooking loss, and improved color characteristics, notably higher redness and lower yellowness values. Transcriptomic profiling and gene expression analysis revealed significant modulation of key muscle growth-related genes, including ACTA1, MYBPC1, TGFβ2, IGF2, and MYH9, indicating adaptive transcriptional responses associated with improved nutrient utilization rather than direct structural muscle alterations. In conclusion, dietary supplementation with a combination of phytase and protease effectively enhances growth performance, feed efficiency, carcass traits, and meat quality in KUB chickens while modulating growth-related gene expression. Multienzyme inclusion represents a promising and cost-effective nutritional strategy for improving productivity and meat quality in native chicken production systems. - Source: PubMed
Publication date: 2026/04/15
Ayuti Siti RaniLamid MirniWarsito Sunaryo HadiArif Mohammad Anam AlKim Eun JoongShin SangsuHamid Iwan SahrialMafruchati MaslichahAkmal MuslimKhairullah Aswin Rafif - Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscular disease in which genetic mutations activate DUX4 expression in skeletal muscle. Currently, there are no approved therapies for FSHD. We developed Delpacibart braxlosiran (del-brax, also known as AOC 1020), an antibody oligonucleotide conjugate (AOC), for the treatment of FSHD that is designed to specifically target and reduce DUX4 mRNA in skeletal muscle. AOC 1020 is composed of DUX4 mRNA-targeting small interfering RNA (siRNA), siDUX4.6, conjugated to a human transferrin receptor 1 (TfR1)-targeting monoclonal antibody to facilitate productive siRNA delivery to muscle. We demonstrate that siDUX4.6 reduces DUX4-regulated gene expression in FSHD patient-derived myotubes in vitro and in skeletal muscle of the ACTA1-MCM; FLExDUX4 FSHD mouse model in vivo. Single systemic intravenous treatment was sufficient to prevent DUX4-induced muscle weakness and fibrosis in this FSHD mouse model and reduce DUX4-regulated genes by ∼75% 8 weeks post-dose. The pharmacokinetic profiles of AOCs with siDUX4.6 were comparable in murine and non-human primate muscle. These data demonstrate the potential of AOC 1020 to treat the underlying cause of FSHD by suppressing DUX4 expression in muscles of patients with FSHD. The safety and efficacy of AOC 1020 is currently being investigated in clinical trials. - Source: PubMed
Malecova BarboraSala DavidMelikian Garineh MJohns RachelErdogan GulinHartmann MarcJordan MaryamArias Joel DannyBhattacharya ArvindMeng QingyingDansereau OliverBeppler Samuel WDoppalapudi Venkata RHuang HanhuaFlanagan William MichaelLevin Arthur A - AllergoOncology has emerged as an interdisciplinary field exploring the interaction between allergic diseases and cancer; however, the lack of stable in vivo models has limited mechanistic investigations. This study aimed to establish an experimental animal model to explore the impact of systemic allergic responses on tumor progression and to provide preliminary insights into the regulatory role of allergy in cancer development. - Source: PubMed
Publication date: 2026/04/08
Fan XiaoyuGuo ShushuZhang WenchaoXu ZeaoSun SimanLi YanHe JiumingJin Hongtao